TORONTO, ON, Canada – May 5, 2026
Takeda Canada Inc. has announced that REVESTIVE® (teduglutide for injection) will now be reimbursed by BC PharmaCare for eligible pediatric and adult patients with Short Bowel Syndrome (SBS) who depend on parenteral support, marking a significant step forward in improving patient access to rare disease treatments in Canada. This reimbursement decision enables broader availability of a therapy shown to reduce dependence on intravenous nutrition, fluids, and electrolytes, addressing a major burden in the management of this life-threatening gastrointestinal condition.
Expanding Access to Rare Disease Treatment
The reimbursement of REVESTIVE under British Columbia’s PharmaCare program represents a critical policy milestone aimed at improving equitable access to advanced therapies for patients with rare digestive disorders. SBS is a condition in which the small intestine cannot absorb sufficient nutrients and fluids, often due to surgical removal or disease-related damage, leading to chronic malnutrition, dehydration, and severe health complications.
Patients frequently rely on long-term parenteral support, which, while life-saving, is associated with serious risks such as infections, liver complications, and reduced quality of life. By enabling access to REVESTIVE, healthcare systems aim to reduce these risks and improve long-term patient outcomes, especially for individuals requiring lifelong care.
Clinical Benefits of REVESTIVE Therapy
Advertisement
REVESTIVE (teduglutide) is a GLP-2 analog therapy designed to enhance intestinal absorption capacity, helping patients reduce or potentially eliminate their dependence on parenteral support over time. Clinical use has shown that some patients experience significant reductions in intravenous nutrition requirements, translating into improved daily functioning, fewer complications, and better overall quality of life.
The therapy is approved in Canada for both adult and pediatric patients aged one year and above, following Health Canada authorization in 2015 for adults and expanded approval in 2019 for children. For a condition affecting approximately 800 Canadians with a mortality rate approaching 40 percent, access to such therapies is not optional, it is critical for survival and long-term management.
Strengthening Healthcare Outcomes and Innovation
Takeda Canada Inc. highlighted that this reimbursement reflects continued progress in translating scientific innovation into real-world patient benefit, particularly in gastrointestinal and rare disease care. REVESTIVE is rooted in the discovery of glucagon-like peptide-2 (GLP-2) at the University of Toronto, showcasing how academic research can evolve into clinically impactful therapies.
Healthcare leaders emphasize that reducing reliance on parenteral support not only improves patient quality of life, but also reduces long-term healthcare system burden associated with complications and hospitalizations. This decision signals a broader trend where reimbursement and access policies are increasingly aligned with innovation in precision therapies, ensuring that patients with rare and complex conditions receive timely and effective treatment options.
Source: Takeda Canada press release
